17
Jul
2006
Part one of a two part interview with David Drake, Director of the Fitzsimons BioBusiness Incubator (FBBi) was posted on the w3w3 network this morning. Part two will be available next Monday. Please contact me if you have any question about FBBi. Listen to the interview podcast (Here). FBBi is dedicated to promoting the growth [...]
24
Feb
2006
At the Boulder Software Club seminar earlier this week a common question was once again raised…how is it that a meaningful ROI may be calculated for a given blog? Well I am not going to address that one here rather I would like to bring to your attention something rather cool I have stumbled upon. [...]
29
Jan
2006
The Business of Science
Posted in Uncategorized
And now for a shameless plug… I would like to quickly highlight for those nascent Colorado life science companies the Fitzsimons BioBusiness Incubator (FBBi). FBBi connects ideas, technologies and people to deliver targeted assistance to start-up companies and entrepreneurs. FBBi works tirelessly to unite industry experts, venture capitalists, private investors, and the researchers that move [...]
28
Jan
2006
It was an impressive 2005 for companies raising venture capital in Colorado. In 2004 total dollars raised was $386.3 million, while 2005 saw a dramatic increase by some 40%, totaling $647.2 million raised (data from Ernst & Young LLP and VentureOne Quarterly Venture Capital Report). Colorado surpassed the U.S. trend numbers; where $22.13 billion in [...]
14
Nov
2005
Are You a Pioneer?
Posted in Uncategorized
The Fitzsimons BioBusiness Incubator (FBBi) has opened her doors, please take a look inside. FBBi is positioned to draw upon Colorado’s experienced entrepreneurial culture and world-renowned research centers to help launch and grow start-up bioscience companies. We encourage pioneering scientists, students, entrepreneurs and companies to participate in FBBi by inquiring to be an advisor to [...]
14
Nov
2005
VentureScape Through 3Q05
Posted in Uncategorized
Who are you going to believe? Is it the VentureOne survey indicating 27 firms have raised $5.91 billion in 3Q05, up from 26 funds closing $5.11 billion in the same period last year, or are you going to buy the National Venture Capital Association data indicating 45 firms raising $5.39 billion in the quarter, likewise [...]
04
Nov
2005
FBBi — The Business of Science
Posted in Uncategorized
Coming soon to a BioWest 2005 conference near you… The Fitzsimons BioBusiness Incubator (FBBi) is dedicated to promoting the growth and success of bioscience businesses in Colorado, with a special emphasis on forming a bioscience cluster at Fitzsimons. FBBi connects ideas, technology, and people to deliver targeted assistance to start-up companies and entrepreneurs. We unite [...]
07
Oct
2005
Brotica: A Chemical Attraction
Posted in Uncategorized
Brotica, Inc. was established in 2002 by a team of six researchers from Colorado State University. Brotica’s objective is to develop environmentally friendly, non-chemical products that fill gaps that exist in modern insect control strategies. Currently, Brotica is developing, manufacturing and selling Interval33™, a patented termite attractant that can be used in conjunction with existing [...]
04
Oct
2005
ApopLogic Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products that target unique apoptotic cell death pathways found in tumor cells and proliferating lymphocytes. The Company was formed in the summer of 2005 to capitalize on the intellectual property of its Scientific Founders, Richard C. Duke and Donald Bellgrau. [...]
02
Oct
2005
In 2002, CU Professors Bob Sievers and John Carpenter, together with Dr. Brian Quinn, founded Aktiv-Dry, LLC. The purpose of the company is to commercialize the use of supercritical carbon dioxide to form micro- and nano-scale particles of thermally sensitive compounds. The pharmaceutical industry is creating a demand for fine dry powders of micron size [...]
25
Sep
2005
GlobeImmune, Inc. recently announced the successful closing of a Series B stock financing raising $34.3 million, to enable continued development of their two lead Tarmogen™ products in the oncology and infectious disease segments. The Series B was led by Lilly Ventures along with Medica Venture Partner, Adams Street Partners, Biogen Idec, Inc., Genentech, Inc., Partners [...]
17
Aug
2005
Denver based Ceragenix Pharmaceuticals (NASDAQ: CGXP.OB), led in part by the research of Chief Scientific Officer Dr. Peter Elias, (UCSF), today was awarded a $1.2M NIH grant to examine the skins barrier function as it relates to eczema vaccinatum, a potentially fatal complication of smallpox vaccination in persons who have or have had eczema. In [...]
15
Jun
2005
Valuation…That Slippery Slope
Posted in Uncategorized
Thank you to Luis at A2VC for providing this interesting tid bit of data. This comes to us from PWC-Thomson Venture Economics-NVCA-Money Tree Survey. Here we are looking at VC valuations for early stage companies before investment and the investment amount. So a company appears to fall in the pre-money valuation range of $8 to [...]
Life Science Deal Flow PARTNERS
-
